Kornimate/medical-research-clean huggingface dataset:
anesthetic agents and acute kidney injury after liver resection surgery

Conditions: Hepatocellular Carcinoma; Hepatoma; Cholangiocarcinoma; Gallbladder Neoplasms

Summary: * it has been shown that patients who undergo liver resection surgery are at high risk for postoperative acute kidney injury (aki). * sevoflurane may increase the risk for postoperative aki because of production of compound-a. * therefore, we have planned to investigate the effects of different anesthetic agents on postoperative renal function. * patients undergoing liver resection surgery are randomized into 2 groups. * one of the groups receives sevoflurane and the other group receives desflurane. * blood and urine specimen are sampled both pre- and postoperatively, and several biomarkers are compared between the groups.

1. design - this is a randomized, observer-blinded, controlled trial. 2. study objectives and hypothesis - the aim of this study is to prove the hypothesis that desflurane is safer than sevoflurane in terms of the association with postoperative acute kidney injury (aki) after liver resection surgery. 3. inclusion and exclusion criteria * inclusion criteria: forty adult patients (20 patients in each group) who are planned to undergo liver resection surgery are included. * exclusion criteria: patients who undergo less invasive liver resection surgery under thoracoscopy or laparoscopy are excluded. patients with chronic kidney disease, or allergic to any anesthetic agents used in the study (e.g., desflurane, sevoflurane, propofol, remifentanil, rocuronium) are also excluded. 4. outcome definition - aki is diagnosed based on rifle creatinine criteria within 72 hours postoperatively. serum creatinine is measured preoperatively, on the day of the surgery, and 1st, 2nd, and 3rd postoperative days. 5. methods * patients are randomized into 2 groups (desflurane group and sevoflurane group) depending on the agent administered during anesthesia * for the quantitative analysis for subclinical aki, urine interleukin-6 (il-6), plasma and urine neutrophil gelatinase-associated lipocalin (ngal), serum cystatin c, urine liver-type fatty acid-binding protein (l-fabp), urine n-acetyl-β-d-glucosaminidase (nag), and urine albumin concentration are measured preoperatively, on the day of the surgery, and 1st postoperative day. * demographic data, preoperative medication, past medical history, perioperative data related to anesthesia and surgery, and data related to outcome are also sampled. * postoperative clinical course is followed until the patients are discharged. * incidence rate of postoperative aki and biomarkers are compared between the groups.

Eligibility criteria:
inclusion criteria: * forty adult patients (20 patients in each group) who are planned to undergo liver resection surgery are included. exclusion criteria: * patients who undergo less invasive resection surgery under thoracoscopy or laparoscopy are excluded. patients with chronic kidney disease, or allergic to any anesthetic agents used in the study are also excluded.

Keywords: hepatectomy
assessment of pacing stimulus conduction and latency measurements in crt-d patients

Conditions: Heart Failure

Summary: the study is designed to collect data on lv latency in crt-d patients by the crt-d and compare measurements to 12-lead ecg data


Eligibility criteria:
inclusion criteria: * patient has been implanted with a crt-d device by biotronik at least 4 weeks before enrollment date * patient successfully implanted with a left ventricular lead * high likelihood of lv latency ≥ 40 ms * lv lead in lateral or postero-lateral position in the coronary venous system * patient is able to understand the nature of the clinical investigation * patient is willing to undergo the required measurements at the investigation site * patient provides written informed consent * age ≥ 18 years exclusion criteria: * patients with irregular ventricular rhythm due to atrial tachycardia * pregnant or breast-feeding women * participation in an interventional clinical investigation

Keywords: crt-d, lv latency
assessment of changes in oral health-related quality of life , oral hygiene status and body growth in cshcn following dental treatment under general anaesthesia

Conditions: Quality of Life; General Anesthesia; Children With Special Health Care Needs; Body Mass Index

Summary: evaluation of the impact of dental treatment under ga on oral health-related quality of life (ohrqol) in children with shcn with severe dental caries with assessment in change in oral health status and the impact on children's weight (wt), height (ht), body mass index (bmi).

the study consisted of clinical dental examinations performed at the time of dga and at the six-month recall, along with ohrqol questionnaires and data drawn from the patients' files. 1. ohrqol will be assessed with the early childhood oral health impact scale (echois) that is composed of items which assess the effect of oral health condition on different aspects of life of the patient . 2. children with mental special health care needs will be recruited from g.a unit in department of pediatric dentistry , faculty of oral and dental medicine cairo university. 3. data will be collected for each of the study participants included age, gender ,medical (type of disability and history of disability) , dental histories and clinical findings were correlated accordingly together with determining the type of disability, anthropometric measures (ht, wt,bmi) that will be measured at baseline and after 3 to 6 months from dental treatment under general anesthesia. 4. the parent or the care giver will be taken as a surrogate measure that will self-complete (ecohis) before and after treatment with follow up after 3 \& 6 months to assess and evaluate children's ohrqol and anthropometric measures update. 5. each ga session included a comprehensive clinical dental examination and full dental rehabilitation. the silness-loe plaque index (pi) was used to assess oral hygiene status. that was measured in the four levels of distal facial, mesial-facial, facial, and lingual of first molars, first premolar and central in each quadrant using mirror and probe. 6. the plaque index was obtained by adding the figures of the four above-mentioned areas of each teeth and dividing it by 4 before recording it in the examination form 7. parents/ caregiver will be asked to consider the last 6 months when responding the questions after ttt , examine effect of oral rehabilitation under ga and its effect on improving quality of life ( pain , eating problems, sleeping problems ,growth parameters as (wt, ht, bmi) and any postoperative complications as postoperative pain and pharynx discomfort or fever

Eligibility criteria:
inclusion criteria: * intellectual disabled children with carious teeth exclusion criteria: * healthy children * children with physical special needs. * refusal of participation. * participation in any other concurrent clinical trials. * presence of any serious medical condition or transmissible diseases such as hepatitis , aids or malignancies. * children whose parents refuse to sign the consent or have no phone no. to enable post-operative contact.
effect of kinesio taping on pain, posture and function in lower cross syndrome

Conditions: Lower Cross Syndrome

Summary: determine the impact of kinesio taping on pain, postural alignment and functional outcomes in individuals with lower cross syndrome.

participants with lower cross syndrome who present to physical therapy department will be screened for eligibility on basis of inclusion and exclusion criteria. group a will receive the treatment with moist hot pack along with stretching of tight erector spinae, hip flexors and strengthening of weak abdominals and gluteal muscles along with kinesiotaping using inhibition and facilitation technique for lcs and group b will receive the treatment with moist hot pack along with stretching of tight erector spinae, hip flexors and strengthening of weak abdominals and gluteal muscles. the patients will receive the treatment sessions 3 days per week for almost 04 weeks. they will be evaluated after the treatment for pain, postural assessment, functional disability in order to check for the effect of the treatment.

Eligibility criteria:
inclusion criteria: * age- 30 to 50 years. * female patients. * anterior pelvic tilting \> 7-10 degrees. * postural imbalance characterized by anterior pelvic tilt, lumbar hyper lordosis, and associated muscle imbalances. * discomfort, pain, or limitations related to the lower back, pelvis, and hips attributed to lcs. * willing to provide informed consent to participate in the study. exclusion criteria: * musculoskeletal pathologies affecting the lower back, pelvis, hips, or lower extremities (e.g., herniated disc, lumbar radiculopathy, lumbar stenosis, hip labral tear). * kinesiotaping interventions for lcs in the past 3 months. * allergies to tape materials or skin sensitivities that might prevent safe tape application. * pregnant individuals due to potential discomfort. * open wounds, infections, or skin conditions at the taping application site. * severe cardiovascular, pulmonary, renal, or neurological diseases. * in other clinical trials involving interventions for lcs.
high dose icotinib in advanced non-small cell lung cancer with egfr 21 exon mutation

Conditions: NSCLC

Summary: this randomized, open-label study is aimed to evaluate the efficacy of high-dose icotinib in treating advanced non-small cell lung cancer patients with positive egfr 21 exon mutation.


Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed stage iiib/iv lung cancer(exclude patients confirmed by sputum cytology) * positive egfr 21 exon mutation or 19 exon deletion * age 18-75 years old with performance status of 0 to 2 * with a measurable disease(longest diameters \>=10mm with spiral computed tomography (ct)and \>=20mm with conventional ct) according to recist criteria * adequate hematological, biochemical and organ functions. exclusion criteria: * severe systemic disease out of control such as unstable or uncompensated respiratory,cardiac,liver,renal diseases. * evidence of interstitial lung diseases * evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the subject to participate in the study
a dental pain study comparing the analgesic efficacy of ibuprofen/caffeine

Conditions: Pain

Summary: an efficacy study assessing analgesic effect of ibuprofen/caffeine in post-surgical dental pain.

the purpose of this study is to assess the analgesic efficacy of a fixed dose combination of ibuprofen/caffeine compared to ibuprofen alone and also to placebo.

Eligibility criteria:
inclusion criteria: * males and females 16 years to 40 years of age (inclusive). * subjects who have undergone outpatient surgical extraction of 3 or more third molars, of which at least 2 must be a partial or complete bony mandibular impaction within 30 days of screening and have met baseline pain criteria as described in this protocol * examined by the attending dentist or physician and medically cleared to participate in the study. exclusion criteria: * evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, metabolic or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing) determined by the investigator to place the subject at increased risk including the presence or history within 2 years of screening of the following medical conditions/disorders: * bleeding disorder; * gastrointestinal ulcer or gastrointestinal bleeding; * paralytic ileus or other gastrointestinal obstructive disorders. * pregnant female subjects; breastfeeding female subjects; fertile male subjects and female subjects of childbearing potential who are unwilling or unable to use a highly effective method of contraception * hypersensitivity to ibuprofen, naproxen, aspirin, or any other nsaid, caffeine, or other component of the product.

Keywords: third molar extraction ibuprofen ibuprofen/caffeine post-surgical dental pain
pharmacokinetics of ceftriaxone free fraction

Conditions: Ceftriaxone Poisoning

Summary: prospective observational follow-up study for the study and modeling of the pharmacokinetics of the free fraction of ceftriaxone in patients treated with high doses of ceftriaxone (greater than or equal to 4 grams per day).

a prospective follow-up observational study to study and model the pharmacokinetics of the ceftriaxone free fraction in patients treated with high doses of ceftriaxone (greater than or equal to 4 grams per day). it is a pilot study that has between 10 and 20 patients. this study will not condition the treatment of patients at any time. the samples will be processed after their extraction. the concentration of the samples will be analyzed using a high-performance gilent infinity liquid chromatograph coupled to a mass spectrometer using positive or negative ionization using electrospray.

Eligibility criteria:
inclusion criteria: * men or women over 55 years of age receiving treatment with high-dose ceftriaxone (minimum 4 grams / day) for any clinical indication in the study period. * creatinine \<1.5 mg / dl * the patient must have received at least 48 hours of treatment with the same previous therapeutic regimen to extraction. * the subject or her representative must give their verbal or written consent to participate in the study. east consent can be revoked at any time without prejudice to the patient. the consent it will be recorded in your medical record. exclusion criteria: * patients under 55 years of age. * creatinine\> 1.5 mg / dl * patient with less than 48 hours of treatment with high-dose ceftriaxone. * subjects with allergy or hypersensitivity to cephalosporins and penicillins. * subjects who do not grant or withdraw their consent. * patients whose concomitant treatment presents possible interactions with the study medication. the possible interactions will be evaluated by staff of the pharmacy service.
the effect of an anesthetic procedure on post operative pain management in carpal tunnel release

Conditions: Pain, Postoperative; Carpal Tunnel Syndrome

Summary: carpal tunnel syndrome patients undergoing carpal tunnel release surgery performed by the pi will receive intra-operative injections of bupivacaine (marcaine). two groups of patients will be randomly selected and will receive either 10cc or 20cc of injection. their post-operative pain scores and usage of post-operative pain medication will be recorded and analyzed.

this randomized control trial will be conducted at the usf department of orthopaedics at the usf health morsani center after receiving approval from the usf institutional review board. patients will be evaluated carpal tunnel syndrome and screened as candidates for carpal tunnel release surgery, following the inclusion and exclusion criteria. the medical record number (mrn) will be used to randomly assign into treatment interventions. group 1 and group 2 will receive 10cc and 20cc of intra-operative intra-carpal tunnel anesthetic injection, respectively. postoperatively, patients will be prescribed an opioid pain medication in congruence with current standard medical practice. patients will be contacted at 24-hours, 48-hours, 72-hours, and at 2-week clinic follow-up by research staff and will be evaluated for pain levels through the likert scale and pain management through use of prescribed and supplemental pain medications. all data will be analyzed through spss v25.

Eligibility criteria:
inclusion criteria: * patient must be undergoing carpal tunnel release surgery performed by pi * emg or ultrasound diagnosed carpal tunnel syndrome exclusion criteria: * co-musculoskeletal injuries
food effect study to evaluate the effect of high-fat meal on the relative bioavailability of pf-07321332 boosted with ritonavir in healthy adult participants

Conditions: Healthy Participants

Summary: this is a phase 1, open label, single dose, randomized, 2-treatment, 2-sequence, 2-period crossover study to evaluate the effect of high-fat meal on the relative bioavailability of pf-07321332 boosted with ritonavir following single dose oral administration of pf-07321332 in combination with ritonavir using 150 mg tablet formulation of pf-07321332 in healthy adult participants.


Eligibility criteria:
inclusion criteria: * male and female participants who are healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, vital signs and 12-lead ecgs. female participants of childbearing potential must have a negative pregnancy test. * body mass index (bmi) of 17.5 to 30.5 kg/m2; and a total body weight \>50 kg (110 lb). exclusion criteria: * positive test result (rt-pcr) for sars-cov-2 infection at the time of screening or day -1. * evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing). * clinically relevant abnormalities requiring treatment (eg, acute myocardial infarction, unstable ischemic conditions, evidence of ventricular dysfunction, serious tachy- or brady brady-arrhythmias) or indicating serious underlying heart disease (eg, prolonged pr interval, cardiomyopathy, heart failure, underlying structural heart disease, wolff parkinson-white syndrome). * any condition possibly affecting drug absorption (eg, gastrectomy, cholecystectomy). * history of human immunodeficiency virus (hiv) infection, hepatitis b, or hepatitis c; positive testing for hiv, hepatitis b surface antigen (hbsag), or hepatitis c antibody (hcvab). hepatitis b vaccination is allowed. * other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality or other conditions or situations related to covid-19 pandemic (eg,. contact with positive case, residence, or travel to an area with high incidence) that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.

Keywords: food effect covid-19 (coronavirus disease 2019) sars-cov (severe acute respiratory syndrome coronavirus)
the effects of angle kappa on clinical outcomes with the panoptix intraocular lens

Conditions: Pseudophakia

Summary: angle kappa is considered a potential factor in explaining suboptimal outcomes with intraocular lenses (iols), particularly multifocal iols. some evidence suggests this is not the case. this study was designed to investigate correlations between angle kappa and post-surgical outcomes with a trifocal iol.

the main complaint of patients who received a presbyopia correcting lens (regardless of the design) are visual disturbances such as glare, halos (rings around lights), starbursts (rays around light sources), mainly at night. the degree of limitation or how bothered patients are varies from patient to patient. to explain these symptoms different theories have been proposed including splitting the light into different focal points which decreases the intensity of the light reaching the retina. most factors are common to all patients who received the lens; however, patients are not equally affected by these symptoms. angle kappa has been considered a factor. angle κ is the angle between the visual axis (straight line that passes through both the center of the pupil and the center of the fovea) and the pupillary axis (perpendicular line to the surface of the cornea that passes through the center of the pupil).

Eligibility criteria:
inclusion criteria: 1. subject is undergoing bilateral lens extraction with intraocular lens implantation (panoptix lens). 2. willing and able to provide written informed consent for participation in the study 3. willing and able to comply with scheduled visits and other study procedures. 4. scheduled to undergo standard cataract surgery with topical anesthesia in both eyes within 6 to 30 days between surgeries. 5. subjects who require an iol power in the range of +6.0 d to +30.0 d only. 6. subjects who require a tfnt00 or tfnt30 to tfnt60 iol. 7. potential postoperative visual acuity of 0.2 logmar (20/32 snellen) or better in both eyes. exclusion criteria: 1. severe preoperative ocular pathology 2. subjects who require a higher toric power than the one available (tfnt60). 3. uncontrolled diabetes. 4. use of any systemic or topical drug known to interfere with visual performance. 5. contact lens use during the active treatment portion of the trial. 6. any concurrent infectious/non-infectious conjunctivitis, keratitis or uveitis. 7. clinically significant corneal dystrophy 8. history of chronic intraocular inflammation. 9. history of retinal detachment. 10. pseudoexfoliation syndrome or any other condition that has the potential to weaken the zonules. 11. previous ocular surgery. 12. severe dry eye 13. pupil abnormalities 14. anesthesia other than topical anesthesia (i.e. retrobulbar, general, etc). 15. any clinically significant, serious or severe medical or psychiatric condition that may increase the risk associated with study participation or may interfere with the interpretation of study results. 16. participation in (or current participation) any ophthalmic investigational drug or ophthalmic device trial within the previous 30 days prior to the start date of this trial.
kcnq1 cascade screening

Conditions: Long QT Syndrome

Summary: the objectives of the protocol are to: (1) evaluate the uptake of cascade screening and preventative therapies after the implementation of a simplified screening process and (2) assess proband and family member perspectives about the return of research results and cascade screening for the kcnq1 thr224met variant. the investigators will conduct a mixed methods study in the old order amish community where the kcnq1 variant is enriched over 100,000-fold compared to other populations. the intervention will offer free, mail-in, saliva-based genetic testing for family members of probands. the rate of uptake of testing and preventative therapy after the intervention is implemented (i.e. when 'simplified' free, mail-in, saliva-based testing was available) will be compared to data from before the intervention (i.e. when 'traditional' $50 blood-based testing was available to family members) when uptake was essentially zero. the primary outcome is the rate of uptake of cascade screening with the intervention ('simplified'). the secondary outcomes include: extent of disclosure of genotype results before and after the intervention, proportion of informed relatives who get screened before and after the intervention, and the uptake of appropriate preventative care (e.g. seeing a cardiologist and/or taking beta-blocker). the tertiary outcomes are demographic characteristics associated with uptake of cascade screening or uptake of preventative therapy. the investigators will also assess qualitative themes surrounding the return of results process and cascade screening using interviews.


Eligibility criteria:
inclusion criteria: * kcnq1thr224met proband or first degree family member exclusion criteria: * family members who have not been contacted by probands

Keywords: cascade screening ethical legal social